Status: Recruiting
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors
This clinical trial is a prospective, dose-escalation, multicenter, single- arm, Phase 1 clinical trial to evaluate the safety, tolerability, PK and preliminary clinical activity of PRAME Antigen-targeted TCR-T Cells (NW-101C) infusion in patients with previously heavily treated, metastatic solid malignant tumors.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Neowise BiotechnologyUpdated: Dec 12, 2025Locations: 1
Eligibility criteria
Age between 18-75 years [+7]
Received the following treatments: Cytotoxic chemotherapy within 2 weeks prior t... [+7]